- Home
- MKZR vs RNAZ Comparison
MKZR vs RNAZ Comparison
Compare MKZR & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- RNAZ
- Stock Information
- Founded
- MKZR 2012
- RNAZ 2016
- Country
- MKZR United States
- RNAZ United States
- Employees
- MKZR N/A
- RNAZ N/A
- Industry
- MKZR
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- MKZR
- RNAZ Health Care
- Exchange
- MKZR Nasdaq
- RNAZ Nasdaq
- Market Cap
- MKZR 10.3M
- RNAZ 8.7M
- IPO Year
- MKZR N/A
- RNAZ 2021
- Fundamental
- Price
- MKZR $5.14
- RNAZ $12.69
- Analyst Decision
- MKZR
- RNAZ Strong Buy
- Analyst Count
- MKZR 0
- RNAZ 1
- Target Price
- MKZR N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- MKZR 32.8K
- RNAZ 421.6K
- Earning Date
- MKZR 11-11-2025
- RNAZ 11-13-2025
- Dividend Yield
- MKZR 19.45%
- RNAZ N/A
- EPS Growth
- MKZR N/A
- RNAZ N/A
- EPS
- MKZR N/A
- RNAZ N/A
- Revenue
- MKZR $21,294,932.00
- RNAZ N/A
- Revenue This Year
- MKZR N/A
- RNAZ N/A
- Revenue Next Year
- MKZR N/A
- RNAZ N/A
- P/E Ratio
- MKZR N/A
- RNAZ N/A
- Revenue Growth
- MKZR 21.25
- RNAZ N/A
- 52 Week Low
- MKZR $3.89
- RNAZ $6.15
- 52 Week High
- MKZR $55.00
- RNAZ $568.26
- Technical
- Relative Strength Index (RSI)
- MKZR 47.64
- RNAZ 48.74
- Support Level
- MKZR $4.84
- RNAZ $12.11
- Resistance Level
- MKZR $5.63
- RNAZ $13.92
- Average True Range (ATR)
- MKZR 0.41
- RNAZ 1.26
- MACD
- MKZR -0.04
- RNAZ -0.24
- Stochastic Oscillator
- MKZR 35.16
- RNAZ 15.14
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.